PTERIDINES EFFECTIVE AS HCV INHIBITORS AND METHODS FOR PRODUCING PTERIDINES Russian patent published in 2012 - IPC C07D475/10 A61K31/517 A61P31/12 

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to the use of pteridines of formula (I), including new pteridine derivatives of formula (VII), their pharmaceutically acceptable salts or esters as HCV-replication inhibitors. The invention also refers to pharmaceutical compositions based on the compounds stated above and a method for HCV-replication inhibition. In general formula

R¹ independently means hydrogen; L means -NR⁸-, -NR⁸-C_1-6alkandiyl or

wherein a cycle indicated by a dashed line together with N and Z forms a cycle containing 5-8 members, and can be substituted by an aromatic monocyclic heterocycle having 6 members in a cycle which contains as cycle members one heteroatom specified in nitrogen, wherein said L cycle is attached to a pteridine cycle by a nitrogen atom; Z means N or CH; R² means hydroxyC_1-6alkyl, phenyl, Het², wherein said phenyl and Het² are independently optionally substituted by one or more substitutes specified in a group consisting of C_1-4alkyl, -COOR⁷, morpholin-4-yl, -CONR^4aR^4b, wherein R^4a and R^4b represent hydrogen, Het¹-C_1-4alkyl; or NR^4aR^4b, wherein R^4a and R^4b represent hydrogen, hydroxy C_1-4alkyl, or can optionally form together with a nitrogen atom whereto attached, a 5-6-members saturated cycle, optionally containing an oxygen atom; R³ means phenyl, Het² . The other radical values are specified in the patent claim.

EFFECT: preparing the compounds applicable as HCV-replication inhibitors.

16 cl, 1 dwg, 4 tbl, 26 ex